IN8bio (NASDAQ:INAB) Stock Price Down 1.8% – Here’s What Happened

IN8bio, Inc. (NASDAQ:INAB) shares traded down 1.8% on Monday. The company traded as low as $1.07 and last traded at $1.09. 21,500 shares changed hands during trading, a decline of 59% from the average session volume of 51,940 shares. The stock had previously closed at $1.11.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of IN8bio in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.

IN8bio Trading Down 6.6%

The business has a fifty day moving average of $1.18 and a 200 day moving average of $1.33. The company has a market capitalization of $10.50 million, a PE ratio of -0.66 and a beta of 0.30.

IN8bio (NASDAQ:INAB) last announced its earnings results on Thursday, August 6th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.09. Equities analysts forecast that IN8bio, Inc. will post -1.49 EPS for the current fiscal year.

IN8bio Company Profile

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.